{"id":471745,"date":"2021-04-06T09:03:30","date_gmt":"2021-04-06T13:03:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=471745"},"modified":"2021-04-06T09:03:30","modified_gmt":"2021-04-06T13:03:30","slug":"sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/","title":{"rendered":"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting"},"content":{"rendered":"
\n

PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) — SOTIO<\/strong><\/a>, a clinical stage immuno-oncology company owned by PPF Group, <\/strong>today announced <\/strong>the presentation of a virtual poster at the 2021 <\/strong>American Association of Cancer Research Annual Meeting<\/strong>. The presentation focuses on <\/strong>preclinical data describing <\/strong> SO<\/strong>T<\/strong>102 <\/strong>which is intended <\/strong>for <\/strong>the <\/strong>treatment of CLDN18.2-expressing solid tumors.<\/strong><\/p>\n

SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin.<\/p>\n

\n Poster Presentation details: <\/strong>\n <\/p>\n

\n Title:<\/strong> SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels<\/p>\n

\n Poster Number:<\/strong> 1204<\/p>\n

\n Session:<\/strong> PO.ET01.05 – New Targets<\/p>\n

\n Presenting Author:<\/strong> Lenka Kyrych Sadilkova, Ph.D.<\/p>\n

\n Date\/ Time: <\/strong>Saturday, April 10, 2021 from 8:30 AM – 11:59 PM EST<\/p>\n

\n Conference Registration Link:<\/strong>
\n https:\/\/myaacr.aacr.org\/LiveEventsList?ac__id=a4j1I000000Yd1r<\/a>\n <\/p>\n

A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.<\/p>\n\n\n\n\n\n\n\n\n\n
\n Company contact:<\/strong>\n <\/td>\n\n Media contact:<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Richard Kapsa<\/strong>\n <\/td>\n\n Kirsten Frazer, Ph.D.<\/strong>\n <\/td>\n<\/tr>\n
\n Head of Communication<\/strong>\n <\/td>\n\n LifeSci Communications<\/strong>\n <\/td>\n<\/tr>\n
\n T: <\/strong>(+420) 224\u00a0174\u00a0448<\/td>\n\n T:<\/strong> +1 646-863-0222<\/td>\n<\/tr>\n
M: (+420) 603\u00a0280\u00a0971<\/td>\n\n kfrazer@lifescicomms.com<\/a>\n <\/td>\n<\/tr>\n
\n kapsa@sotio.com<\/a>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About SOTIO<\/strong>\n <\/p>\n

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO\u2019s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies, CAR T platform and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. For more information, please visit the company\u2019s website at www.sotio.com<\/a>.<\/p>\n

SOTIO is a registered trademark of SOTIO a.s. in selected countries.<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) — SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors. SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin. Poster Presentation details: Title: SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target … <\/p>\n

Continue reading “SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-471745","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) — SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors. SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin. Poster Presentation details: Title: SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target … Continue reading "SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-06T13:03:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting\",\"datePublished\":\"2021-04-06T13:03:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/\"},\"wordCount\":313,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/\",\"name\":\"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==\",\"datePublished\":\"2021-04-06T13:03:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting - Market Newsdesk","og_description":"PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) — SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors. SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin. Poster Presentation details: Title: SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target … Continue reading \"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-06T13:03:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting","datePublished":"2021-04-06T13:03:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/"},"wordCount":313,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/","name":"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==","datePublished":"2021-04-06T13:03:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxMjIxMCM0MTA3NzY1IzUwMDA3MjQ0MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sotio-to-present-preclinical-results-describing-sot102-as-treatment-of-solid-tumors-at-the-american-association-of-cancer-research-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=471745"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/471745\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=471745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=471745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=471745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}